ABCG2 and cancer: Overall, our findings suggest that furmonertinib effectively countered MDR in cancer cells overexpressing ABCB1 or ABCG2, achieved through the inhibition of drug efflux activity for both transporters, rather than by inducing changes in the protein expression of ABCB1 and ABCG2.